单克隆抗体用于治疗溃疡性结肠炎的研究进展

Progress of monoclonal antibody in treatment of ulcerative colitis

溃疡性结肠炎(UC)发病机制复杂,与免疫因素及炎性介质等因素相关。单克隆抗体因为能特异性结合并选择性杀伤靶细胞、体内呈靶向性分布、不良反应少,所以成为治疗中重度UC的研究热点,其中包括抗肿瘤坏死因子类单抗(如英夫利昔单抗、阿达木单抗、戈利木单抗),α4β7整合素抗体(如维多珠单抗、etrolizumab、SHP647),白细胞介素(IL)-12和IL-23拮抗剂等。对治疗UC单克隆抗体的作用机制和临床疗效研究进展进行综述,以期为该类新药的研发及临床应用提供依据。

The pathogenesis of ulcerative colitis(UC)is complex and related to immune factors and inflammatory mediators.Monoclonal antibodies for specific binding and selectively kill target cells,in vivo distribution is targeting property,less adverse reaction,so become the focus in the treatment of moderately severe UC,including anti-tumor necrosis factor subclass monoclonal antibody(such as infliximab,adamumab,golimumab),Anti-α4β7 integrin antibody(such as vitorizumab,etrolizumab,SHP647),interleukin(IL)-12 and IL-23 antagonists,etc.The mechanism of action and clinical efficacy of monoclonal antibody against UC were reviewed in order to provide evidence for the development and clinical application of this new drug.